University of Ioannina
Σύγκριση των επιδράσεων της ινσουλίνης Degludec με το συνδυασμό ινσουλίνης Degludec/liraglutide στο μεταβολισμό των λιπιδίων και λιποπρωτεϊνών του ορού σε ασθενείς με σακχαρώδη διαβήτη τύπου 2
Abstract
dc:descriptionIntroduction: The administration of the fixed-dose combination of Insulin Degludec and Liraglutide (IDegLira) has been associated with changes in the fasting lipid profile of diabetic patients, while the effect of the combination on apoB-containing lipoprotein subclasses’ values remains unclear. In the present study, we assessed the effect of IDegLira combination concerning the fasting lipid parameters, serum apolipoproteins, apoB-containing lipoprotein subclasses and HDL lipidome in diabetic patients in clinical practice.Materials and Methods: Seventy two patients with type 2 diabetes mellitus and glycated hemoglobin levels greater than 7% on oral antidiabetics were included. Forty two patients received the IDegLira combination, while the remainig 30 patients received insulin degludec (IDeg), with a treatment duration of 3 months. Anthropometric and lipid, as well as carbohydrate metabolism parameters were assessed before initiation and following 3 months of treatment. The levels of apoB-containing lipoprotein subclasses were measured by the Lipoprint method. The lipid composition of HDL lipoproteins was assessed via nuclear proton magnetic resonance spectroscopy (1H NMR).Results: Administration of IDegLira resulted in a statistically significant reduction of total and LDL cholesterol levels by 7.5 mg/dl, (p = 0.0137) and 5.9 mg/dl, (p = 0.0149) respectively. A trend towards triglyceride decrease was also noted, while HDL cholesterol levels remained unchanged. Treatment with the IDegLira combination resulted in a trend towards decrease of apolipoproteins A1 and B levels. Furthermore, a non-significant increase in the levels of small dense LDL (sdLDL) particles was observed. However, the change in sdLDL concentration significantly correlated to respective changes in triglyceride levels (r = 0.494, p = 0.01). Thus, patients in whom the combination caused a significant decrease in triglycerides showed a parallel decrease in the sdLDL concentration by approximately 20% (p <0.05). The changes in the levels of lipid parameters were significantly greater than those observed in the IDeg group, in which no significant changes of the lipid profile were observed, as well as in the levels of apoB-containing lipoprotein subclasses. Moreover, in a sub-analysis of the present study, it was found that in patients in whom the combination of IDegLira led to a decrease in triglycerides, a significantly greater reduction in glycemic and anthropometric parameters was observed. Additionally, IDegLira administration resulted in significant enrichment of HDL particles’ core in esterified cholesterol and depletion of TGs content. Administration of IDegLira combination induced a statistically significant lower content in saturated and higher in unsaturated fatty acids (linoleic acid, eicosapentaenoic and arachidonic acids and docosahexaenoic acid). No significant changes were observed in the IDeg group.Conclusions: Administration of IDegLira combination is accompanied by a decrease in the concentrations of total and LDL cholesterol, while the levels of sdLDL are only reduced in patients experiencing a significant decrease in triglycerides following drug administration. Administration of IDegLira combination induced an atheroprotective shift in fatty acid pattern of HDLs. The contribution of the changes in fasting lipid parameters of diabetic patients to cardiovascular risk reduction observed after treatment with liraglutide in clinical trials cannot be excluded.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pappa, Eleni
- Παππά, Ελένη
Subjects
dc:subject × 16- Λιραγλουτίδη
- Ινσουλίνη Degludec
- Λιποπρωτεΐνες
- Μικρά πυκνά LDL σωματίδια
- Λιπιδική σύσταση HDL λιποπρωτεϊνών
- liraglutide
- Insulin degludec
- Lipoproteins
- Small dense LDL particles
- HDL lipidome
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
dc:rights- Statement dc:rights
-
- BY_4_0
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49478